
<!-- saved from url=(0053)https://static.btloader.com/safeFrame.html?upapi=true -->
<html><head><meta http-equiv="Content-Type" content="text/html; charset=windows-1252"></head><body marginwidth="0" marginheight="0" data-new-gr-c-s-check-loaded="14.1237.0" data-gr-ext-installed=""><img src="./08c23735-2e63-43fd-9b9f-f301661e22c2" style="display:none" width="0" height="0" alt="" border="0"><iframe id="te-clr1-4db88d86-d9af-417d-874a-d55f0a2bc7de-icon" frameborder="0" scrolling="no" style="cursor: pointer; display: block; position: absolute; overflow: hidden; margin: 0px; padding: 0px; pointer-events: auto; transform: none !important; background: transparent !important; opacity: 0.8; z-index: 100002; width: 19px; height: 15px; left: 709px; top: 0px;" src="./saved_resource(5).html"></iframe><div id="dv_pp_o5l28VJYj9wr"><script type="text/adtag">
 
<div style="width:728px; height: 90px; overflow:hidden">
        <script type="text/javascript">
        window.adxcel_macros_data = {
                "__GDPR_CONSENT_755__":"${GDPR_CONSENT_755}",
                "__GDPR__":"${GDPR}",
                "__RANDOM__":"1075091022"
                }
        </scr+ipt>

        <script type="text/javascript" src="https://twc-assets.artsai.com/ibm_campaigns/viiv/cabenuva25/p_592851_728_tag.js?nature=dfp&cb=1075091022&ctp=https://ma2-tr.contextweb.com/bh/ct2?i=o5l28VJYj9wr~a=90663cf045df9d04355d5b3e7cfa198847a5520b~agi=220691~ts=J0pC3WobeFruSQQEg10OePL44k8B4tKf~es=2~gdprc=CQL4_0AQL4_0AEXqkAENA0EgAAAAAEPgACiQAAAUHALMNCogCrIgJCDQMAoEAKgrCAigQAAAAkDRAQAkDAp2BgEusJEAIAEAAwQAgABRkACAAASABCIAIACgQAAQCBQAAAAAAAQAMDAAGACwEAgABAdAhTAggUCwASMwIhTAgCgSCAlsqEEgCBBXCAIscCCAREwUAAAJABWAAACwWAxJICViQQJcQbQAAEACAQQgVCKTowBBAmbLVTiAAAEAAAAEAAAA~c=2270939~p=561967~pu=https%3A%2F%2Fwww.hockey-reference.com%2Fleagues%2FNHL_2015.html~s=indexexchange.com~u=&idfa=&device_id=&touch=1"></scr+ipt>
</div>
<script src="https://cdn.doubleverify.com/dvtp_src.js?ctx=17280926&cmp=33038412&sid=5856115&plc=411640758&adsrv=1&btreg=&btadsrv=&crt=&tagtype=&dvtagver=6.1.src" type="text/javascript"></scr+ipt>
</script>
<script language="javascript" type="text/javascript" src="./dvbs_src.js.download">
</script><script type="text/javascript" src="./dvbs_src_internal138.js.download"></script><script data-uk="dv_baseHandler__342696073129" onerror="(function dv_onError(evt) {
    var elm = evt &amp;&amp; evt.target || {};
    var globalScope = dv_getDVErrorGlobalScope(elm);
    if (globalScope) {
        globalScope.onError(dv_getScriptSRC(elm));
    }
})({target:this});" onload="(function dv_onResponse(evt) {
    var elm = evt &amp;&amp; evt.target || {};
    var globalScope = dv_getDVErrorGlobalScope(elm);
    if (globalScope) {
        var scriptSRC = dv_getScriptSRC(elm);
        if (!globalScope.isJSONPCalled) {
            globalScope.onResponse(scriptSRC);
        }
    }
})({target:this});" type="text/javascript" src="./verify.js.download"></script>
 
<div style="width:728px; height: 90px; overflow:hidden">
        <script type="text/javascript">
        window.adxcel_macros_data = {
                "__GDPR_CONSENT_755__":"${GDPR_CONSENT_755}",
                "__GDPR__":"${GDPR}",
                "__RANDOM__":"1075091022"
                }
        </script>

        <script type="text/javascript" src="./p_592851_728_tag.js.download"></script><div id="adxcel_id_68199663animbox" style="position:absolute; width:728px; height:90px; left:0px; top:0px;"><style type="text/css">.class_hide { display: none !important; opacity: 0 !important; position: absolute; left: 0px; top: 0px; width: 0px; height: 0px; }.class_show { display: block !important; opacity: 1 !important; }.scale_text_image { -webkit-transform-origin: top left; -webkit-transform: scale(0.5, 0.5); transform-origin: top left; transform: scale(0.5, 0.5); width: 1456px !important; height: 180px !important; }div, img { margin: 0px; padding: 0px; border: 0px; outline: none; box-sizing: border-box; -moz-box-sizing: border-box; -webkit-box-sizing: border-box; display: block; }img { -webkit-transform: translateZ(0) scale(1.0, 1.0); -webkit-backface-visibility: hidden; image-rendering: -webkit-optimize-contrast; }.animation_unbranded728_v1 { position: absolute; width: 728px; height: 90px; left: 0px; top: 0px; overflow: hidden; -webkit-transform-origin: 0px 0px; }.wrapper_image_unbranded728_v1 { position: absolute; width: 728px; height: 90px; left: 0px; top: 0px; overflow: hidden; }.image_unbranded728_v1 { position: absolute; width: 728px; height: 90px; left: 0px; top: 0px; }.wrapper_adchoice_unbranded728_v1 { position: absolute; width: 18px; height: 15px; left: 710px; top: 0px; overflow: hidden; }.adchoice_unbranded728_v1 { position: absolute; width: 18px; height: 15px; left: 0px; top: 0px; cursor: pointer; }.wrapper_seewhatastudyfound_unbranded728_v1 { position: absolute; width: 0px; height: 0px; left: 0px; top: 0px; overflow: hidden; }.link_seewhatastudyfound_unbranded728_v1 { position: absolute; width: 728px; height: 90px; left: 0px; top: 0px; }.wrapper_seewhatastudyshowed_unbranded728_v1 { position: absolute; width: 0px; height: 0px; left: 0px; top: 0px; overflow: hidden; }.link_seewhatastudyshowed_unbranded728_v1 { position: absolute; width: 728px; height: 90px; left: 0px; top: 0px; }.wrapper_seestudyresults_unbranded728_v1 { position: absolute; width: 0px; height: 0px; left: 0px; top: 0px; overflow: hidden; }.link_seestudyresults_unbranded728_v1 { position: absolute; width: 728px; height: 90px; left: 0px; top: 0px; }</style></div><div id="adxcel_id_68199663enginebox" style="position:absolute; dysplay:none; width:1px; height:1px; left:0px; top:0px;"></div><a id="adxcel_id_68199663href" target="_blank" href="https://ma2-tr.contextweb.com/bh/ct2?i=o5l28VJYj9wr~a=90663cf045df9d04355d5b3e7cfa198847a5520b~agi=220691~ts=J0pC3WobeFruSQQEg10OePL44k8B4tKf~es=2~gdprc=CQL4_0AQL4_0AEXqkAENA0EgAAAAAEPgACiQAAAUHALMNCogCrIgJCDQMAoEAKgrCAigQAAAAkDRAQAkDAp2BgEusJEAIAEAAwQAgABRkACAAASABCIAIACgQAAQCBQAAAAAAAQAMDAAGACwEAgABAdAhTAggUCwASMwIhTAgCgSCAlsqEEgCBBXCAIscCCAREwUAAAJABWAAACwWAxJICViQQJcQbQAAEACAQQgVCKTowBBAmbLVTiAAAEAAAAEAAAA~c=2270939~p=561967~pu=https://www.hockey-reference.com/leagues/NHL_2015.html~s=indexexchange.com~u=https://ad.doubleclick.net/ddm/trackclk/N744860.620333PULSEPOINT/B33038412.411640758;dc_trk_aid=603514170;dc_trk_cid=228071324;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};ltd=;dc_tdv=1"><div id="adxcel_id_68199663hrefbox" style="display: inline; overflow: hidden; position: absolute; width: 728px; height: 90px; left: 0px; top: 0px; opacity: 1;"><div id="adxcel_id_68199663container" style="overflow: hidden; position: absolute; width: 728px; height: 90px; left: 0px; top: 0px; opacity: 1; display: inline;"><div id="adxcel_id_68199663_animation_efficacy728_v1" style="display:inline" class="animation_efficacy728_v1"><div id="adxcel_id_68199663_wrapper_background_efficacy728_v1" style="display:inline" class="wrapper_background_efficacy728_v1"><img id="adxcel_id_68199663_logobig_efficacy728_v1" style="display:none" class="logobig_efficacy728_v1 scale_text_image"><div id="adxcel_id_68199663_angle_efficacy728_v1" style="display:inline" class="angle_efficacy728_v1"></div><div id="adxcel_id_68199663_darkblueangle_efficacy728_v1" style="display:inline" class="darkblueangle_efficacy728_v1"></div></div><div id="adxcel_id_68199663_wrapper_image_efficacy728_v1" style="display:inline" class="wrapper_image_efficacy728_v1"><div id="adxcel_id_68199663_bluepanel_efficacy728_v1" style="display:inline" class="bluepanel_efficacy728_v1"></div><div id="adxcel_id_68199663_darkbluepanel_efficacy728_v1" style="display:inline" class="darkbluepanel_efficacy728_v1"></div><img id="adxcel_id_68199663_image_efficacy728_v1" style="display:none" class="image_efficacy728_v1 scale_text_image"><img id="adxcel_id_68199663_logosmall_efficacy728_v1" style="display:none" class="logosmall_efficacy728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_headline11_efficacy728_v1" style="display:inline" class="wrapper_headline11_efficacy728_v1"><div id="adxcel_id_68199663_inner_headline11_efficacy728_v1" style="display:inline" class="inner_headline11_efficacy728_v1"><img id="adxcel_id_68199663_headline11_efficacy728_v1" style="display:none" class="headline11_efficacy728_v1 scale_text_image"></div><div id="adxcel_id_68199663_inner_headline12_efficacy728_v1" style="display:inline" class="inner_headline12_efficacy728_v1"><img id="adxcel_id_68199663_headline12_efficacy728_v1" style="display:none" class="headline12_efficacy728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_explore_efficacy728_v1" style="display:inline" class="button_explore_efficacy728_v1"><div id="adxcel_id_68199663_wrapper_cta_explore_efficacy728_v1" style="display:inline" class="wrapper_cta_explore_efficacy728_v1"><img id="adxcel_id_68199663_cta_explore_efficacy728_v1" style="display:none" class="cta_explore_efficacy728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_explore_efficacy728_v1" style="display:inline" class="wrapper_arrow_explore_efficacy728_v1"><img id="adxcel_id_68199663_arrow_explore_efficacy728_v1" style="display:none" class="arrow_explore_efficacy728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_see_efficacy728_v1" style="display:inline" class="button_see_efficacy728_v1"><div id="adxcel_id_68199663_wrapper_cta_see_efficacy728_v1" style="display:inline" class="wrapper_cta_see_efficacy728_v1"><img id="adxcel_id_68199663_cta_see_efficacy728_v1" style="display:none" class="cta_see_efficacy728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_see_efficacy728_v1" style="display:inline" class="wrapper_arrow_see_efficacy728_v1"><img id="adxcel_id_68199663_arrow_see_efficacy728_v1" style="display:none" class="arrow_see_efficacy728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_find_efficacy728_v1" style="display:inline" class="button_find_efficacy728_v1"><div id="adxcel_id_68199663_wrapper_cta_find_efficacy728_v1" style="display:inline" class="wrapper_cta_find_efficacy728_v1"><img id="adxcel_id_68199663_cta_find_efficacy728_v1" style="display:none" class="cta_find_efficacy728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_find_efficacy728_v1" style="display:inline" class="wrapper_arrow_find_efficacy728_v1"><img id="adxcel_id_68199663_arrow_find_efficacy728_v1" style="display:none" class="arrow_find_efficacy728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_borderleft_efficacy728_v1" style="display:inline" class="borderleft_efficacy728_v1"></div><div id="adxcel_id_68199663_borderright_efficacy728_v1" style="display:inline" class="borderright_efficacy728_v1"></div><div id="adxcel_id_68199663_bordertop_efficacy728_v1" style="display:inline" class="bordertop_efficacy728_v1"></div><div id="adxcel_id_68199663_borderbottom_efficacy728_v1" style="display:inline" class="borderbottom_efficacy728_v1"></div><div id="adxcel_id_68199663_wrapper_adchoice_efficacy728_v1" style="display:inline" class="wrapper_adchoice_efficacy728_v1"><img id="adxcel_id_68199663_adchoice_efficacy728_v1" style="display:none" class="adchoice_efficacy728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_animation_patient728_v1" style="display:inline" class="animation_patient728_v1"><div id="adxcel_id_68199663_wrapper_image_patient728_v1" style="display:inline" class="wrapper_image_patient728_v1"><img id="adxcel_id_68199663_image_patient728_v1" style="display:none" class="image_patient728_v1 scale_text_image"><img id="adxcel_id_68199663_logo_patient728_v1" style="display:none" class="logo_patient728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_headline11_patient728_v1" style="display:inline" class="wrapper_headline11_patient728_v1"><div id="adxcel_id_68199663_inner_headline11_patient728_v1" style="display:inline" class="inner_headline11_patient728_v1 class_hide"><img id="adxcel_id_68199663_headline11_patient728_v1" style="display:none" class="headline11_patient728_v1 scale_text_image"></div><div id="adxcel_id_68199663_inner_headline12_patient728_v1" style="display:inline" class="inner_headline12_patient728_v1 class_hide"><img id="adxcel_id_68199663_headline12_patient728_v1" style="display:none" class="headline12_patient728_v1 scale_text_image"></div><div id="adxcel_id_68199663_inner_headline11_left_patient728_v1" style="display:inline" class="inner_headline11_left_patient728_v1 class_hide"><img id="adxcel_id_68199663_headline11_left_patient728_v1" style="display:none" class="headline11_left_patient728_v1 scale_text_image"></div><div id="adxcel_id_68199663_inner_headline12_left_patient728_v1" style="display:inline" class="inner_headline12_left_patient728_v1 class_hide"><img id="adxcel_id_68199663_headline12_left_patient728_v1" style="display:none" class="headline12_left_patient728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_see_patient728_v1" style="display:inline" class="button_see_patient728_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_see_patient728_v1" style="display:inline" class="wrapper_cta_see_patient728_v1"><img id="adxcel_id_68199663_cta_see_patient728_v1" style="display:none" class="cta_see_patient728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_see_patient728_v1" style="display:inline" class="wrapper_arrow_see_patient728_v1"><img id="adxcel_id_68199663_arrow_see_patient728_v1" style="display:none" class="arrow_see_patient728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_view_patient728_v1" style="display:inline" class="button_view_patient728_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_view_patient728_v1" style="display:inline" class="wrapper_cta_view_patient728_v1"><img id="adxcel_id_68199663_cta_view_patient728_v1" style="display:none" class="cta_view_patient728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_view_patient728_v1" style="display:inline" class="wrapper_arrow_view_patient728_v1"><img id="adxcel_id_68199663_arrow_view_patient728_v1" style="display:none" class="arrow_view_patient728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_find_patient728_v1" style="display:inline" class="button_find_patient728_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_find_patient728_v1" style="display:inline" class="wrapper_cta_find_patient728_v1"><img id="adxcel_id_68199663_cta_find_patient728_v1" style="display:none" class="cta_find_patient728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_find_patient728_v1" style="display:inline" class="wrapper_arrow_find_patient728_v1"><img id="adxcel_id_68199663_arrow_find_patient728_v1" style="display:none" class="arrow_find_patient728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_see_patient728_left_v1" style="display:inline" class="button_see_patient728_left_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_see_patient728_left_v1" style="display:inline" class="wrapper_cta_see_patient728_left_v1"><img id="adxcel_id_68199663_cta_see_patient728_left_v1" style="display:none" class="cta_see_patient728_left_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_see_patient728_v1" style="display:inline" class="wrapper_arrow_see_patient728_v1"><img id="adxcel_id_68199663_arrow_see_patient728_left_v1" style="display:none" class="arrow_see_patient728_left_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_view_patient728_left_v1" style="display:inline" class="button_view_patient728_left_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_view_patient728_left_v1" style="display:inline" class="wrapper_cta_view_patient728_left_v1"><img id="adxcel_id_68199663_cta_view_patient728_left_v1" style="display:none" class="cta_view_patient728_left_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_view_patient728_left_v1" style="display:inline" class="wrapper_arrow_view_patient728_left_v1"><img id="adxcel_id_68199663_arrow_view_patient728_left_v1" style="display:none" class="arrow_view_patient728_left_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_find_patient728_left_v1" style="display:inline" class="button_find_patient728_left_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_find_patient728_left_v1" style="display:inline" class="wrapper_cta_find_patient728_left_v1"><img id="adxcel_id_68199663_cta_find_patient728_left_v1" style="display:none" class="cta_find_patient728_left_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_find_patient728_left_v1" style="display:inline" class="wrapper_arrow_find_patient728_left_v1"><img id="adxcel_id_68199663_arrow_find_patient728_left_v1" style="display:none" class="arrow_find_patient728_left_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_borderleft_patient728_v1" style="display:inline" class="borderleft_patient728_v1"></div><div id="adxcel_id_68199663_borderright_patient728_v1" style="display:inline" class="borderright_patient728_v1"></div><div id="adxcel_id_68199663_bordertop_patient728_v1" style="display:inline" class="bordertop_patient728_v1"></div><div id="adxcel_id_68199663_borderbottom_patient728_v1" style="display:inline" class="borderbottom_patient728_v1"></div><div id="adxcel_id_68199663_wrapper_adchoice_patient728_v1" style="display:inline" class="wrapper_adchoice_patient728_v1"><img id="adxcel_id_68199663_adchoice_patient728_v1" style="display:none" class="adchoice_patient728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_animation_patient728_dop_v1" style="display:inline" class="animation_patient728_dop_v1"><div id="adxcel_id_68199663_wrapper_image_patient728_dop_v1" style="display:inline" class="wrapper_image_patient728_dop_v1"><img id="adxcel_id_68199663_image_patient728_dop_v1" style="display:none" class="image_patient728_dop_v1 scale_text_image"><img id="adxcel_id_68199663_logo_patient728_dop_v1" style="display:none" class="logo_patient728_dop_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_headline11_patient728_dop_v1" style="display:inline" class="wrapper_headline11_patient728_dop_v1"><div id="adxcel_id_68199663_inner_headline11_patient728_dop_v1" style="display:inline" class="inner_headline11_patient728_dop_v1 class_hide"><img id="adxcel_id_68199663_headline11_patient728_dop_v1" style="display:none" class="headline11_patient728_dop_v1 scale_text_image"></div><div id="adxcel_id_68199663_inner_headline11_left_patient728_dop_v1" style="display:inline" class="inner_headline11_left_patient728_dop_v1 class_hide"><img id="adxcel_id_68199663_headline11_left_patient728_dop_v1" style="display:none" class="headline11_left_patient728_dop_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_see_patient728_dop_v1" style="display:inline" class="button_see_patient728_dop_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_see_patient728_dop_v1" style="display:inline" class="wrapper_cta_see_patient728_dop_v1"><img id="adxcel_id_68199663_cta_see_patient728_dop_v1" style="display:none" class="cta_see_patient728_dop_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_see_patient728_dop_v1" style="display:inline" class="wrapper_arrow_see_patient728_dop_v1"><img id="adxcel_id_68199663_arrow_see_patient728_dop_v1" style="display:none" class="arrow_see_patient728_dop_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_view_patient728_dop_v1" style="display:inline" class="button_view_patient728_dop_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_view_patient728_dop_v1" style="display:inline" class="wrapper_cta_view_patient728_dop_v1"><img id="adxcel_id_68199663_cta_view_patient728_dop_v1" style="display:none" class="cta_view_patient728_dop_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_view_patient728_dop_v1" style="display:inline" class="wrapper_arrow_view_patient728_dop_v1"><img id="adxcel_id_68199663_arrow_view_patient728_dop_v1" style="display:none" class="arrow_view_patient728_dop_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_find_patient728_dop_v1" style="display:inline" class="button_find_patient728_dop_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_find_patient728_dop_v1" style="display:inline" class="wrapper_cta_find_patient728_dop_v1"><img id="adxcel_id_68199663_cta_find_patient728_dop_v1" style="display:none" class="cta_find_patient728_dop_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_find_patient728_dop_v1" style="display:inline" class="wrapper_arrow_find_patient728_dop_v1"><img id="adxcel_id_68199663_arrow_find_patient728_dop_v1" style="display:none" class="arrow_find_patient728_dop_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_see_patient728_left_dop_v1" style="display:inline" class="button_see_patient728_left_dop_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_see_patient728_left_dop_v1" style="display:inline" class="wrapper_cta_see_patient728_left_dop_v1"><img id="adxcel_id_68199663_cta_see_patient728_left_dop_v1" style="display:none" class="cta_see_patient728_left_dop_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_see_patient728_left_dop_v1" style="display:inline" class="wrapper_arrow_see_patient728_left_dop_v1"><img id="adxcel_id_68199663_arrow_see_patient728_left_dop_v1" style="display:none" class="arrow_see_patient728_left_dop_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_view_patient728_left_dop_v1" style="display:inline" class="button_view_patient728_left_dop_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_view_patient728_left_dop_v1" style="display:inline" class="wrapper_cta_view_patient728_left_dop_v1"><img id="adxcel_id_68199663_cta_view_patient728_left_dop_v1" style="display:none" class="cta_view_patient728_left_dop_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_view_patient728_left_dop_v1" style="display:inline" class="wrapper_arrow_view_patient728_left_dop_v1"><img id="adxcel_id_68199663_arrow_view_patient728_left_dop_v1" style="display:none" class="arrow_view_patient728_left_dop_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_find_patient728_left_dop_v1" style="display:inline" class="button_find_patient728_left_dop_v1 class_hide"><div id="adxcel_id_68199663_wrapper_cta_find_patient728_left_dop_v1" style="display:inline" class="wrapper_cta_find_patient728_left_dop_v1"><img id="adxcel_id_68199663_cta_find_patient728_left_dop_v1" style="display:none" class="cta_find_patient728_left_dop_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_find_patient728_left_dop_v1" style="display:inline" class="wrapper_arrow_find_patient728_left_dop_v1"><img id="adxcel_id_68199663_arrow_find_patient728_left_dop_v1" style="display:none" class="arrow_find_patient728_left_dop_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_borderleft_patient728_dop_v1" style="display:inline" class="borderleft_patient728_dop_v1"></div><div id="adxcel_id_68199663_borderright_patient728_dop_v1" style="display:inline" class="borderright_patient728_dop_v1"></div><div id="adxcel_id_68199663_bordertop_patient728_dop_v1" style="display:inline" class="bordertop_patient728_dop_v1"></div><div id="adxcel_id_68199663_borderbottom_patient728_dop_v1" style="display:inline" class="borderbottom_patient728_dop_v1"></div><div id="adxcel_id_68199663_wrapper_adchoice_patient728_dop_v1" style="display:inline" class="wrapper_adchoice_patient728_dop_v1"><img id="adxcel_id_68199663_adchoice_patient728_dop_v1" style="display:none" class="adchoice_patient728_dop_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_animation_unmet728_v1" style="display:inline" class="animation_unmet728_v1"><div id="adxcel_id_68199663_wrapper_image_unmet728_v1" style="display:inline" class="wrapper_image_unmet728_v1"><img id="adxcel_id_68199663_image_unmet728_v1" style="display:none" class="image_unmet728_v1 scale_text_image"><img id="adxcel_id_68199663_logo_unmet728_v1" style="display:none" class="logo_unmet728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_headline11_unmet728_v1" style="display:inline" class="wrapper_headline11_unmet728_v1"><div id="adxcel_id_68199663_inner_headline11_unmet728_v1" style="display:inline" class="inner_headline11_unmet728_v1"><img id="adxcel_id_68199663_headline11_unmet728_v1" style="display:none" class="headline11_unmet728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_learn_unmet728_v1" style="display:inline" class="button_learn_unmet728_v1"><div id="adxcel_id_68199663_wrapper_cta_learn_unmet728_v1" style="display:inline" class="wrapper_cta_learn_unmet728_v1"><img id="adxcel_id_68199663_cta_learn_unmet728_v1" style="display:none" class="cta_learn_unmet728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_learn_unmet728_v1" style="display:inline" class="wrapper_arrow_learn_unmet728_v1"><img id="adxcel_id_68199663_arrow_learn_unmet728_v1" style="display:none" class="arrow_learn_unmet728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_see_unmet728_v1" style="display:inline" class="button_see_unmet728_v1"><div id="adxcel_id_68199663_wrapper_cta_see_unmet728_v1" style="display:inline" class="wrapper_cta_see_unmet728_v1"><img id="adxcel_id_68199663_cta_see_unmet728_v1" style="display:none" class="cta_see_unmet728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_see_unmet728_v1" style="display:inline" class="wrapper_arrow_see_unmet728_v1"><img id="adxcel_id_68199663_arrow_see_unmet728_v1" style="display:none" class="arrow_see_unmet728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_button_find_unmet728_v1" style="display:inline" class="button_find_unmet728_v1"><div id="adxcel_id_68199663_wrapper_cta_find_unmet728_v1" style="display:inline" class="wrapper_cta_find_unmet728_v1"><img id="adxcel_id_68199663_cta_find_unmet728_v1" style="display:none" class="cta_find_unmet728_v1 scale_text_image"></div><div id="adxcel_id_68199663_wrapper_arrow_find_unmet728_v1" style="display:inline" class="wrapper_arrow_find_unmet728_v1"><img id="adxcel_id_68199663_arrow_find_unmet728_v1" style="display:none" class="arrow_find_unmet728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_borderleft_unmet728_v1" style="display:inline" class="borderleft_unmet728_v1"></div><div id="adxcel_id_68199663_borderright_unmet728_v1" style="display:inline" class="borderright_unmet728_v1"></div><div id="adxcel_id_68199663_bordertop_unmet728_v1" style="display:inline" class="bordertop_unmet728_v1"></div><div id="adxcel_id_68199663_borderbottom_unmet728_v1" style="display:inline" class="borderbottom_unmet728_v1"></div><div id="adxcel_id_68199663_wrapper_adchoice_unmet728_v1" style="display:inline" class="wrapper_adchoice_unmet728_v1"><img id="adxcel_id_68199663_adchoice_unmet728_v1" style="display:none" class="adchoice_unmet728_v1 scale_text_image"></div></div><div id="adxcel_id_68199663_animation_unbranded728_v1" style="display:inline" class="animation_unbranded728_v1"><div id="adxcel_id_68199663_wrapper_image_unbranded728_v1" style="display:inline" class="wrapper_image_unbranded728_v1"><img id="adxcel_id_68199663_image_unbranded728_v1" style="display: inline;" class="image_unbranded728_v1 scale_text_image" skip-pkg="1" src="./Image3_unbranded728_v1.jpg" data-src="motion_viiv728_v5/unbranded728_v1/Image3_unbranded728_v1.jpg"></div><div id="adxcel_id_68199663_wrapper_adchoice_unbranded728_v1" style="display:inline" class="wrapper_adchoice_unbranded728_v1"><img id="adxcel_id_68199663_adchoice_unbranded728_v1" style="display: inline;" class="adchoice_unbranded728_v1" src="./AdChoice_unbranded728_v1.png" data-src="motion_viiv728_v5/unbranded728_v1/AdChoice_unbranded728_v1.png"></div></div></div></div><div id="adxcel_id_68199663overlay" style="display:inline; overflow:hidden; position:absolute; width:728px; height:90px; left:0px; top:0px; opacity:0.0;background:#FFFFFF;"></div></a><div id="adxcel_id_68199663_wrapper_panel_efficacy728_v1" data-wrapper="efficacy" style="display:none" class="wrapper_panel_efficacy728_v1 class_hide">CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA &lt;50 copies/mL) on<br>a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.</div><div id="adxcel_id_68199663_wrapper_isi_efficacy728_v1" style="display:none" class="wrapper_isi_efficacy728_v1"><div id="adxcel_id_68199663_textarea_isi_efficacy728_v1" class="textarea_isi_efficacy728_v1"><p class="isi_title_main_efficacy728_v1">IMPORTANT SAFETY INFORMATION</p><p class="isi_title_part_efficacy728_v1">CONTRAINDICATIONS</p><ul class="isi_list_efficacy728_v1"><li><span>Do not use CABENUVA in patients with previous hypersensitivity reaction to cabotegravir or rilpivirine</span></li><li><span>Do not use CABENUVA in patients receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, systemic dexamethasone (&gt;1 dose), and St John?s wort</span></li></ul><p class="isi_title_part_efficacy728_v1">WARNINGS AND PRECAUTIONS</p><p class="isi_title_efficacy728_v1">Hypersensitivity Reactions:</p><ul class="isi_list_efficacy728_v1"><li><span>Serious or severe hypersensitivity reactions have been reported in association with other integrase inhibitors and could occur with CABENUVA</span></li><li><span>Hypersensitivity reactions, including cases of drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported during postmarketing experience with rilpivirine-containing regimens. While some skin reactions were accompanied by constitutional symptoms such as fever, other skin reactions were associated with organ dysfunctions, including elevations in hepatic serum biochemistries</span></li><li><span>Discontinue CABENUVA immediately if signs or symptoms of hypersensitivity reactions develop.<br>Clinical status, including liver transaminases, should be monitored and appropriate therapy initiated. Cabotegravir and rilpivirine oral lead-in may be used<br>to help identify patients who may be at risk of a hypersensitivity reaction</span></li></ul><p class="isi_title_efficacy728_v1">Post-Injection Reactions:</p><ul class="isi_list_efficacy728_v1"><li><span>Serious post-injection reactions (reported in less than 1% of subjects) were reported within minutes after the injection of rilpivirine, including dyspnea, bronchospasm, agitation, abdominal cramping, rash/<br>urticaria, dizziness, flushing, sweating, oral numbness, changes in blood pressure, and pain (e.g., back and chest). These events may have been associated with accidental intravenous administration and began to resolve within a few minutes after the injection</span></li><li><span>Carefully follow the Instructions for Use when<br>preparing and administering CABENUVA. The suspensions should be injected slowly via<br>intramuscular injection and avoid accidental intravenous administration. Observe patients briefly (approximately 10 minutes) after the injection. If a<br>post-injection reaction occurs, monitor and treat as clinically indicated</span></li></ul><p class="isi_title_efficacy728_v1">Hepatotoxicity:</p><ul class="isi_list_efficacy728_v1"><li><span>Hepatotoxicity has been reported in patients receiving cabotegravir or rilpivirine with or without known pre-<br>existing hepatic disease or identifiable risk factors</span></li><li><span>Patients with underlying liver disease or marked elevations in transaminases prior to treatment may be<br>at increased risk for worsening or development of transaminase elevations</span></li><li><span>Monitoring of liver chemistries is recommended and treatment with CABENUVA should be discontinued if hepatotoxicity is suspected</span></li></ul><p class="isi_title_efficacy728_v1">Depressive Disorders:</p><ul class="isi_list_efficacy728_v1"><li><span>Depressive disorders (including depressed mood, depression, major depression, mood altered, mood swings, dysphoria, negative thoughts, suicidal<br>ideation, suicide attempt) have been reported with CABENUVA or the individual products</span></li><li><span>Promptly evaluate patients with depressive symptoms</span></li></ul><p class="isi_title_efficacy728_v1">Risk of Adverse Reactions or Loss of Virologic<br>Response Due to Drug Interactions:</p><ul class="isi_list_efficacy728_v1"><li><span>The concomitant use of CABENUVA and other drugs may result in known or potentially significant drug interactions (see Contraindications and Drug Interactions)</span></li><li><span>Rilpivirine doses 3 and 12 times higher than the recommended oral dosage can prolong the QTc<br>interval</span></li><li><span>CABENUVA should be used with caution in<br>combination with drugs with a known risk of Torsade<br>de Pointes</span></li></ul><p class="isi_title_efficacy728_v1">Long-Acting Properties and Potential Associated<br>Risks with CABENUVA:</p><ul class="isi_list_efficacy728_v1"><li><span>Residual concentrations of cabotegravir and rilpivirine may remain in the systemic circulation of patients for prolonged periods (up to 12 months or longer). Select appropriate patients who agree to the required<br>monthly or every-2-month injection dosing schedule because non-adherence could lead to loss of virologic response and development of resistance</span></li><li><span>To minimize the potential risk of developing viral resistance, it is essential to initiate an alternative, fully suppressive antiretroviral regimen no later than 1<br>month after the final injection doses of CABENUVA when dosed monthly and no later than 2 months after the final injections of CABENUVA when dosed every<br>2 months. If virologic failure is suspected, switch the patient to an alternative regimen as soon as possible</span></li></ul><p class="isi_title_part_efficacy728_v1">ADVERSE REACTIONS</p><ul class="isi_list_efficacy728_v1"><li><span>The most common adverse reactions in adults (incidence &#8805;2%, all grades) treated with CABENUVA were injection site reactions, pyrexia, fatigue,<br>headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash</span></li><li><span>The safety of CABENUVA in adolescents is expected to be similar to adults</span></li></ul><p class="isi_title_part_efficacy728_v1">DRUG INTERACTIONS</p><ul class="isi_list_efficacy728_v1"><li><span>Refer to the applicable full Prescribing Information for important drug interactions with CABENUVA,<br>VOCABRIA (cabotegravir), or EDURANT (rilpivirine)</span></li><li><span>Because CABENUVA is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not<br>recommended</span></li><li><span>Drugs that are strong inducers of UGT1A1 or UGT1A9 are expected to decrease the plasma concentrations of cabotegravir. Drugs that induce or inhibit CYP3A may affect the plasma concentrations of rilpivirine</span></li><li><span>CABENUVA should be used with caution in<br>combination with drugs with a known risk of Torsade<br>de Pointes</span></li></ul><p class="isi_title_part_efficacy728_v1">USE IN SPECIFIC POPULATIONS</p><ul class="isi_list_efficacy728_v1"><li><span><b>Pregnancy:</b> There are insufficient human data on the use of CABENUVA during pregnancy to adequately assess a drug-associated risk for birth defects and miscarriage. Discuss the benefit-risk of using<br>CABENUVA during pregnancy and conception and consider that cabotegravir and rilpivirine are detected<br>in systemic circulation for up to 12 months or longer after discontinuing injections of CABENUVA. An Antiretroviral Pregnancy Registry has been<br>established</span></li><li><span><b>Lactation:</b> Potential risks of breastfeeding include<br>HIV-1 transmission, developing viral resistance in<br>HIV-positive infants, and adverse reactions in a<br>breastfed infant</span></li></ul><p class="isi_close_efficacy728_v1">Please see <a href="https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF" target="_blank">full Prescribing Information</a> for CABENUVA.</p><p></p><p class="isi_close_efficacy728_v1"><b>Reference: 1.</b> Ramgopal MN, Castagna A, Cazanave C, et al. SOLAR 12-month results?randomized switch trial of CAB + RPV LA vs. oral B/FTC/TAF. Presented at: CROI<br>2023; Virtual and Seattle, WA; Oral Presentation.</p><p></p><p class="isi_close_efficacy728_v1">Trademarks are property of their respective owners.</p><p class="isi_close_efficacy728_v1">©2024 ViiV Healthcare or licensor.</p><p class="isi_close_efficacy728_v1">CBRBNNR240004 February 2024</p><p class="isi_close_efficacy728_v1">Produced in USA.</p></div></div><div id="adxcel_id_68199663_wrapper_footnote_efficacy728_v1" data-wrapper="efficacy" style="display:none" class="wrapper_footnote_efficacy728_v1 class_hide"><span id="adxcel_id_68199663_footnote_linkparent_efficacy728_v1" class="footnote_linkparent_efficacy728_v1"><a id="adxcel_id_68199663_footnote_link_efficacy728_v1" class="footnote_link_efficacy728_v1" href="https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF" target="_blank">Click here</a> for full Prescribing Information.</span><span id="adxcel_id_68199663_footnote_bottomtext_efficacy728_v1" class="footnote_bottomtext_efficacy728_v1">For US Healthcare Professionals Only.</span></div><div id="adxcel_id_68199663_wrapper_exploreefficacyresults_efficacy728_v1" data-wrapper="efficacy" data-cta="C0" style="display:none" class="wrapper_exploreefficacyresults_efficacy728_v1 class_hide"><a id="adxcel_id_68199663_link_exploreefficacyresults_efficacy728_v1" style="display:inline" class="link_exploreefficacyresults_efficacy728_v1" href="https://www.cabenuvahcp.com/efficacy/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seestudydata_efficacy728_v1" data-wrapper="efficacy" data-cta="C1" style="display:none" class="wrapper_seestudydata_efficacy728_v1 class_hide"><a id="adxcel_id_68199663_link_seestudydata_efficacy728_v1" style="display:inline" class="link_seestudydata_efficacy728_v1" href="https://www.cabenuvahcp.com/efficacy/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_findoutmore_efficacy728_v1" data-wrapper="efficacy" data-cta="C2" style="display:none" class="wrapper_findoutmore_efficacy728_v1 class_hide"><a id="adxcel_id_68199663_link_findoutmore_efficacy728_v1" style="display:inline" class="link_findoutmore_efficacy728_v1" href="https://www.cabenuvahcp.com/efficacy/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_panel_patient728_v1" data-wrapper="patient" style="display:none" class="wrapper_panel_patient728_v1 class_hide">CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA &lt;50 copies/mL) on<br>a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.</div><div id="adxcel_id_68199663_wrapper_isi_patient728_v1" style="display:none" class="wrapper_isi_patient728_v1"><div id="adxcel_id_68199663_textarea_isi_patient728_v1" class="textarea_isi_patient728_v1"><p class="isi_title_main_patient728_v1">IMPORTANT SAFETY INFORMATION</p><p class="isi_title_part_patient728_v1">CONTRAINDICATIONS</p><ul class="isi_list_patient728_v1"><li><span>Do not use CABENUVA in patients with previous hypersensitivity reaction to cabotegravir or rilpivirine</span></li><li><span>Do not use CABENUVA in patients receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, systemic dexamethasone (&gt;1 dose), and St John?s wort</span></li></ul><p class="isi_title_part_patient728_v1">WARNINGS AND PRECAUTIONS</p><p class="isi_title_patient728_v1">Hypersensitivity Reactions:</p><ul class="isi_list_patient728_v1"><li><span>Serious or severe hypersensitivity reactions have been reported in association with other integrase inhibitors and could occur with CABENUVA</span></li><li><span>Hypersensitivity reactions, including cases of drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported during postmarketing experience with rilpivirine-containing regimens. While some skin reactions were accompanied by constitutional symptoms such as fever, other skin reactions were associated with organ dysfunctions, including elevations in hepatic serum biochemistries</span></li><li><span>Discontinue CABENUVA immediately if signs or symptoms of hypersensitivity reactions develop.<br>Clinical status, including liver transaminases, should be monitored and appropriate therapy initiated. Cabotegravir and rilpivirine oral lead-in may be used<br>to help identify patients who may be at risk of a hypersensitivity reaction</span></li></ul><p class="isi_title_patient728_v1">Post-Injection Reactions:</p><ul class="isi_list_patient728_v1"><li><span>Serious post-injection reactions (reported in less than 1% of subjects) were reported within minutes after the injection of rilpivirine, including dyspnea, bronchospasm, agitation, abdominal cramping, rash/<br>urticaria, dizziness, flushing, sweating, oral numbness, changes in blood pressure, and pain (e.g., back and chest). These events may have been associated with accidental intravenous administration and began to resolve within a few minutes after the injection</span></li><li><span>Carefully follow the Instructions for Use when<br>preparing and administering CABENUVA. The suspensions should be injected slowly via<br>intramuscular injection and avoid accidental intravenous administration. Observe patients briefly (approximately 10 minutes) after the injection. If a<br>post-injection reaction occurs, monitor and treat as clinically indicated</span></li></ul><p class="isi_title_patient728_v1">Hepatotoxicity:</p><ul class="isi_list_patient728_v1"><li><span>Hepatotoxicity has been reported in patients receiving cabotegravir or rilpivirine with or without known pre-<br>existing hepatic disease or identifiable risk factors</span></li><li><span>Patients with underlying liver disease or marked elevations in transaminases prior to treatment may be<br>at increased risk for worsening or development of transaminase elevations</span></li><li><span>Monitoring of liver chemistries is recommended and treatment with CABENUVA should be discontinued if hepatotoxicity is suspected</span></li></ul><p class="isi_title_patient728_v1">Depressive Disorders:</p><ul class="isi_list_patient728_v1"><li><span>Depressive disorders (including depressed mood, depression, major depression, mood altered, mood swings, dysphoria, negative thoughts, suicidal<br>ideation, suicide attempt) have been reported with CABENUVA or the individual products</span></li><li><span>Promptly evaluate patients with depressive symptoms</span></li></ul><p class="isi_title_patient728_v1">Risk of Adverse Reactions or Loss of Virologic<br>Response Due to Drug Interactions:</p><ul class="isi_list_patient728_v1"><li><span>The concomitant use of CABENUVA and other drugs may result in known or potentially significant drug interactions (see Contraindications and Drug Interactions)</span></li><li><span>Rilpivirine doses 3 and 12 times higher than the recommended oral dosage can prolong the QTc<br>interval</span></li><li><span>CABENUVA should be used with caution in<br>combination with drugs with a known risk of Torsade<br>de Pointes</span></li></ul><p class="isi_title_patient728_v1">Long-Acting Properties and Potential Associated<br>Risks with CABENUVA:</p><ul class="isi_list_patient728_v1"><li><span>Residual concentrations of cabotegravir and rilpivirine may remain in the systemic circulation of patients for prolonged periods (up to 12 months or longer). Select appropriate patients who agree to the required<br>monthly or every-2-month injection dosing schedule because non-adherence could lead to loss of virologic response and development of resistance</span></li><li><span>To minimize the potential risk of developing viral resistance, it is essential to initiate an alternative, fully suppressive antiretroviral regimen no later than 1<br>month after the final injection doses of CABENUVA when dosed monthly and no later than 2 months after the final injections of CABENUVA when dosed every<br>2 months. If virologic failure is suspected, switch the patient to an alternative regimen as soon as possible</span></li></ul><p class="isi_title_part_patient728_v1">ADVERSE REACTIONS</p><ul class="isi_list_patient728_v1"><li><span>The most common adverse reactions in adults (incidence &#8805;2%, all grades) treated with CABENUVA were injection site reactions, pyrexia, fatigue,<br>headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash</span></li><li><span>The safety of CABENUVA in adolescents is expected to be similar to adults</span></li></ul><p class="isi_title_part_patient728_v1">DRUG INTERACTIONS</p><ul class="isi_list_patient728_v1"><li><span>Refer to the applicable full Prescribing Information for important drug interactions with CABENUVA,<br>VOCABRIA (cabotegravir), or EDURANT (rilpivirine)</span></li><li><span>Because CABENUVA is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not<br>recommended</span></li><li><span>Drugs that are strong inducers of UGT1A1 or UGT1A9 are expected to decrease the plasma concentrations of cabotegravir. Drugs that induce or inhibit CYP3A may affect the plasma concentrations of rilpivirine</span></li><li><span>CABENUVA should be used with caution in<br>combination with drugs with a known risk of Torsade<br>de Pointes</span></li></ul><p class="isi_title_part_patient728_v1">USE IN SPECIFIC POPULATIONS</p><ul class="isi_list_patient728_v1"><li><span><b>Pregnancy:</b> There are insufficient human data on the use of CABENUVA during pregnancy to adequately assess a drug-associated risk for birth defects and miscarriage. Discuss the benefit-risk of using<br>CABENUVA during pregnancy and conception and consider that cabotegravir and rilpivirine are detected<br>in systemic circulation for up to 12 months or longer after discontinuing injections of CABENUVA. An Antiretroviral Pregnancy Registry has been<br>established</span></li><li><span><b>Lactation:</b> Potential risks of breastfeeding include<br>HIV-1 transmission, developing viral resistance in<br>HIV-positive infants, and adverse reactions in a<br>breastfed infant</span></li></ul><p class="isi_close_patient728_v1">Please see <a href="https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF" target="_blank">full Prescribing Information</a> for CABENUVA.</p><p></p><p class="isi_close_patient728_v1"><b>Reference: 1.</b> Ramgopal MN, Castagna A, Cazanave C, et al. SOLAR 12-month results?randomized switch trial of CAB + RPV LA vs. oral B/FTC/TAF. Presented at: CROI<br>2023; Virtual and Seattle, WA; Oral Presentation.</p><p></p><p class="isi_close_patient728_v1">Trademarks are property of their respective owners.</p><p class="isi_close_patient728_v1">©2024 ViiV Healthcare or licensor.</p><p class="isi_close_patient728_v1">CBRBNNR240005 February 2024</p><p class="isi_close_patient728_v1">Produced in USA.</p></div></div><div id="adxcel_id_68199663_wrapper_footnote_patient728_v1" data-wrapper="patient" style="display:none" class="wrapper_footnote_patient728_v1 class_hide"><span id="adxcel_id_68199663_footnote_linkparent_patient728_v1" class="footnote_linkparent_patient728_v1"><a id="adxcel_id_68199663_footnote_link_patient728_v1" class="footnote_link_patient728_v1" href="https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF" target="_blank">Click here</a> for full Prescribing Information.</span><span id="adxcel_id_68199663_footnote_bottomtext_patient728_v1" class="footnote_bottomtext_patient728_v1">For US Healthcare Professionals Only.</span></div><div id="adxcel_id_68199663_wrapper_viewstudyfindings_patient728_v1" data-wrapper="patient" data-cta="C0" style="display:none" class="wrapper_viewstudyfindings_patient728_v1 class_hide"><a id="adxcel_id_68199663_link_viewstudyfindings_patient728_v1" style="display:inline" class="link_viewstudyfindings_patient728_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seepreferenceresults_patient728_v1" data-wrapper="patient" data-cta="C1" style="display:none" class="wrapper_seepreferenceresults_patient728_v1 class_hide"><a id="adxcel_id_68199663_link_seepreferenceresults_patient728_v1" style="display:inline" class="link_seepreferenceresults_patient728_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_findoutmore_patient728_v1" data-wrapper="patient" data-cta="C2" style="display:none" class="wrapper_findoutmore_patient728_v1 class_hide"><a id="adxcel_id_68199663_link_findoutmore_patient728_v1" style="display:inline" class="link_findoutmore_patient728_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_viewstudyfindings_patient728_left_v1" data-wrapper="patient_left" data-cta="C0" style="display:none" class="wrapper_viewstudyfindings_patient728_left_v1 class_hide"><a id="adxcel_id_68199663_link_viewstudyfindings_patient728_left_v1" style="display:inline" class="link_viewstudyfindings_patient728_left_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seepreferenceresults_patient728_left_v1" data-wrapper="patient_left" data-cta="C1" style="display:none" class="wrapper_seepreferenceresults_patient728_left_v1 class_hide"><a id="adxcel_id_68199663_link_seepreferenceresults_patient728_left_v1" style="display:inline" class="link_seepreferenceresults_patient728_left_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_findoutmore_patient728_left_v1" data-wrapper="patient_left" data-cta="C2" style="display:none" class="wrapper_findoutmore_patient728_left_v1 class_hide"><a id="adxcel_id_68199663_link_findoutmore_patient728_left_v1" style="display:inline" class="link_findoutmore_patient728_left_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_panel_patient728_dop_v1" data-wrapper="patient_dop" style="display:none" class="wrapper_panel_patient728_dop_v1 class_hide">CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA &lt;50 copies/mL) on<br>a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.</div><div id="adxcel_id_68199663_wrapper_isi_patient728_dop_v1" style="display:none" class="wrapper_isi_patient728_dop_v1"><div id="adxcel_id_68199663_textarea_isi_patient728_dop_v1" class="textarea_isi_patient728_dop_v1"><p class="isi_title_main_patient728_dop_v1">IMPORTANT SAFETY INFORMATION</p><p class="isi_title_part_patient728_dop_v1">CONTRAINDICATIONS</p><ul class="isi_list_patient728_dop_v1"><li><span>Do not use CABENUVA in patients with previous hypersensitivity reaction to cabotegravir or rilpivirine</span></li><li><span>Do not use CABENUVA in patients receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, systemic dexamethasone (&gt;1 dose), and St John?s wort</span></li></ul><p class="isi_title_part_patient728_dop_v1">WARNINGS AND PRECAUTIONS</p><p class="isi_title_patient728_dop_v1">Hypersensitivity Reactions:</p><ul class="isi_list_patient728_dop_v1"><li><span>Serious or severe hypersensitivity reactions have been reported in association with other integrase inhibitors and could occur with CABENUVA</span></li><li><span>Hypersensitivity reactions, including cases of drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported during postmarketing experience with rilpivirine-containing regimens. While some skin reactions were accompanied by constitutional symptoms such as fever, other skin reactions were associated with organ dysfunctions, including elevations in hepatic serum biochemistries</span></li><li><span>Discontinue CABENUVA immediately if signs or symptoms of hypersensitivity reactions develop.<br>Clinical status, including liver transaminases, should be monitored and appropriate therapy initiated. Cabotegravir and rilpivirine oral lead-in may be used<br>to help identify patients who may be at risk of a hypersensitivity reaction</span></li></ul><p class="isi_title_patient728_dop_v1">Post-Injection Reactions:</p><ul class="isi_list_patient728_dop_v1"><li><span>Serious post-injection reactions (reported in less than 1% of subjects) were reported within minutes after the injection of rilpivirine, including dyspnea, bronchospasm, agitation, abdominal cramping, rash/<br>urticaria, dizziness, flushing, sweating, oral numbness, changes in blood pressure, and pain (e.g., back and chest). These events may have been associated with accidental intravenous administration and began to resolve within a few minutes after the injection</span></li><li><span>Carefully follow the Instructions for Use when<br>preparing and administering CABENUVA. The suspensions should be injected slowly via<br>intramuscular injection and avoid accidental intravenous administration. Observe patients briefly (approximately 10 minutes) after the injection. If a<br>post-injection reaction occurs, monitor and treat as clinically indicated</span></li></ul><p class="isi_title_patient728_dop_v1">Hepatotoxicity:</p><ul class="isi_list_patient728_dop_v1"><li><span>Hepatotoxicity has been reported in patients receiving cabotegravir or rilpivirine with or without known pre-<br>existing hepatic disease or identifiable risk factors</span></li><li><span>Patients with underlying liver disease or marked elevations in transaminases prior to treatment may be<br>at increased risk for worsening or development of transaminase elevations</span></li><li><span>Monitoring of liver chemistries is recommended and treatment with CABENUVA should be discontinued if hepatotoxicity is suspected</span></li></ul><p class="isi_title_patient728_dop_v1">Depressive Disorders:</p><ul class="isi_list_patient728_dop_v1"><li><span>Depressive disorders (including depressed mood, depression, major depression, mood altered, mood swings, dysphoria, negative thoughts, suicidal<br>ideation, suicide attempt) have been reported with CABENUVA or the individual products</span></li><li><span>Promptly evaluate patients with depressive symptoms</span></li></ul><p class="isi_title_patient728_dop_v1">Risk of Adverse Reactions or Loss of Virologic<br>Response Due to Drug Interactions:</p><ul class="isi_list_patient728_dop_v1"><li><span>The concomitant use of CABENUVA and other drugs may result in known or potentially significant drug interactions (see Contraindications and Drug Interactions)</span></li><li><span>Rilpivirine doses 3 and 12 times higher than the recommended oral dosage can prolong the QTc<br>interval</span></li><li><span>CABENUVA should be used with caution in<br>combination with drugs with a known risk of Torsade<br>de Pointes</span></li></ul><p class="isi_title_patient728_dop_v1">Long-Acting Properties and Potential Associated<br>Risks with CABENUVA:</p><ul class="isi_list_patient728_dop_v1"><li><span>Residual concentrations of cabotegravir and rilpivirine may remain in the systemic circulation of patients for prolonged periods (up to 12 months or longer). Select appropriate patients who agree to the required<br>monthly or every-2-month injection dosing schedule because non-adherence could lead to loss of virologic response and development of resistance</span></li><li><span>To minimize the potential risk of developing viral resistance, it is essential to initiate an alternative, fully suppressive antiretroviral regimen no later than 1<br>month after the final injection doses of CABENUVA when dosed monthly and no later than 2 months after the final injections of CABENUVA when dosed every<br>2 months. If virologic failure is suspected, switch the patient to an alternative regimen as soon as possible</span></li></ul><p class="isi_title_part_patient728_dop_v1">ADVERSE REACTIONS</p><ul class="isi_list_patient728_dop_v1"><li><span>The most common adverse reactions in adults (incidence &#8805;2%, all grades) treated with CABENUVA were injection site reactions, pyrexia, fatigue,<br>headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash</span></li><li><span>The safety of CABENUVA in adolescents is expected to be similar to adults</span></li></ul><p class="isi_title_part_patient728_dop_v1">DRUG INTERACTIONS</p><ul class="isi_list_patient728_dop_v1"><li><span>Refer to the applicable full Prescribing Information for important drug interactions with CABENUVA,<br>VOCABRIA (cabotegravir), or EDURANT (rilpivirine)</span></li><li><span>Because CABENUVA is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not<br>recommended</span></li><li><span>Drugs that are strong inducers of UGT1A1 or UGT1A9 are expected to decrease the plasma concentrations of cabotegravir. Drugs that induce or inhibit CYP3A may affect the plasma concentrations of rilpivirine</span></li><li><span>CABENUVA should be used with caution in<br>combination with drugs with a known risk of Torsade<br>de Pointes</span></li></ul><p class="isi_title_part_patient728_dop_v1">USE IN SPECIFIC POPULATIONS</p><ul class="isi_list_patient728_dop_v1"><li><span><b>Pregnancy:</b> There are insufficient human data on the use of CABENUVA during pregnancy to adequately assess a drug-associated risk for birth defects and miscarriage. Discuss the benefit-risk of using<br>CABENUVA during pregnancy and conception and consider that cabotegravir and rilpivirine are detected<br>in systemic circulation for up to 12 months or longer after discontinuing injections of CABENUVA. An Antiretroviral Pregnancy Registry has been<br>established</span></li><li><span><b>Lactation:</b> Potential risks of breastfeeding include<br>HIV-1 transmission, developing viral resistance in<br>HIV-positive infants, and adverse reactions in a<br>breastfed infant</span></li></ul><p class="isi_close_patient728_dop_v1">Please see <a href="https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF" target="_blank">full Prescribing Information</a> for CABENUVA.</p><p></p><p class="isi_close_patient728_dop_v1"><b>Reference: 1.</b> Ramgopal MN, Castagna A, Cazanave C, et al. SOLAR 12-month results?randomized switch trial of CAB + RPV LA vs. oral B/FTC/TAF. Presented at: CROI<br>2023; Virtual and Seattle, WA; Oral Presentation.</p><p></p><p class="isi_close_patient728_dop_v1">Trademarks are property of their respective owners.</p><p class="isi_close_patient728_dop_v1">©2024 ViiV Healthcare or licensor.</p><p class="isi_close_patient728_dop_v1">CBRBNNR240005 February 2024</p><p class="isi_close_patient728_dop_v1">Produced in USA.</p></div></div><div id="adxcel_id_68199663_wrapper_footnote_patient728_dop_v1" data-wrapper="patient_dop" style="display:none" class="wrapper_footnote_patient728_dop_v1 class_hide"><span id="adxcel_id_68199663_footnote_linkparent_patient728_dop_v1" class="footnote_linkparent_patient728_dop_v1"><a id="adxcel_id_68199663_footnote_link_patient728_dop_v1" class="footnote_link_patient728_dop_v1" href="https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF" target="_blank">Click here</a> for full Prescribing Information.</span><span id="adxcel_id_68199663_footnote_bottomtext_patient728_dop_v1" class="footnote_bottomtext_patient728_dop_v1">For US Healthcare Professionals Only.</span></div><div id="adxcel_id_68199663_wrapper_viewstudyfindings_patient728_dop_v1" data-wrapper="patient_dop" data-cta="C0" style="display:none" class="wrapper_viewstudyfindings_patient728_dop_v1 class_hide"><a id="adxcel_id_68199663_link_viewstudyfindings_patient728_dop_v1" style="display:inline" class="link_viewstudyfindings_patient728_dop_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seepreferenceresults_patient728_dop_v1" data-wrapper="patient_dop" data-cta="C1" style="display:none" class="wrapper_seepreferenceresults_patient728_dop_v1 class_hide"><a id="adxcel_id_68199663_link_seepreferenceresults_patient728_dop_v1" style="display:inline" class="link_seepreferenceresults_patient728_dop_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_findoutmore_patient728_dop_v1" data-wrapper="patient_dop" data-cta="C2" style="display:none" class="wrapper_findoutmore_patient728_dop_v1 class_hide"><a id="adxcel_id_68199663_link_findoutmore_patient728_dop_v1" style="display:inline" class="link_findoutmore_patient728_dop_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_viewstudyfindings_patient728_left_dop_v1" data-wrapper="patient_left_dop" data-cta="C0" style="display:none" class="wrapper_viewstudyfindings_patient728_left_dop_v1 class_hide"><a id="adxcel_id_68199663_link_viewstudyfindings_patient728_left_dop_v1" style="display:inline" class="link_viewstudyfindings_patient728_left_dop_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seepreferenceresults_patient728_left_dop_v1" data-wrapper="patient_left_dop" data-cta="C1" style="display:none" class="wrapper_seepreferenceresults_patient728_left_dop_v1 class_hide"><a id="adxcel_id_68199663_link_seepreferenceresults_patient728_left_dop_v1" style="display:inline" class="link_seepreferenceresults_patient728_left_dop_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_findoutmore_patient728_left_dop_v1" data-wrapper="patient_left_dop" data-cta="C2" style="display:none" class="wrapper_findoutmore_patient728_left_dop_v1 class_hide"><a id="adxcel_id_68199663_link_findoutmore_patient728_left_dop_v1" style="display:inline" class="link_findoutmore_patient728_left_dop_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_panel_unmet728_v1" data-wrapper="unmet" style="display:none" class="wrapper_panel_unmet728_v1 class_hide">CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA &lt;50 copies/mL) on<br>a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.</div><div id="adxcel_id_68199663_wrapper_isi_unmet728_v1" style="display:none" class="wrapper_isi_unmet728_v1"><div id="adxcel_id_68199663_textarea_isi_unmet728_v1" class="textarea_isi_unmet728_v1"><p class="isi_title_main_unmet728_v1">IMPORTANT SAFETY INFORMATION</p><p class="isi_title_part_unmet728_v1">CONTRAINDICATIONS</p><ul class="isi_list_unmet728_v1"><li><span>Do not use CABENUVA in patients with previous hypersensitivity reaction to cabotegravir or rilpivirine</span></li><li><span>Do not use CABENUVA in patients receiving carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, systemic dexamethasone (&gt;1 dose), and St John?s wort</span></li></ul><p class="isi_title_part_unmet728_v1">WARNINGS AND PRECAUTIONS</p><p class="isi_title_unmet728_v1">Hypersensitivity Reactions:</p><ul class="isi_list_unmet728_v1"><li><span>Serious or severe hypersensitivity reactions have been reported in association with other integrase inhibitors and could occur with CABENUVA</span></li><li><span>Hypersensitivity reactions, including cases of drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported during postmarketing experience with rilpivirine-containing regimens. While some skin reactions were accompanied by constitutional symptoms such as fever, other skin reactions were associated with organ dysfunctions, including elevations in hepatic serum biochemistries</span></li><li><span>Discontinue CABENUVA immediately if signs or symptoms of hypersensitivity reactions develop.<br>Clinical status, including liver transaminases, should be monitored and appropriate therapy initiated. Cabotegravir and rilpivirine oral lead-in may be used<br>to help identify patients who may be at risk of a hypersensitivity reaction</span></li></ul><p class="isi_title_unmet728_v1">Post-Injection Reactions:</p><ul class="isi_list_unmet728_v1"><li><span>Serious post-injection reactions (reported in less than 1% of subjects) were reported within minutes after the injection of rilpivirine, including dyspnea, bronchospasm, agitation, abdominal cramping, rash/<br>urticaria, dizziness, flushing, sweating, oral numbness, changes in blood pressure, and pain (e.g., back and chest). These events may have been associated with accidental intravenous administration and began to resolve within a few minutes after the injection</span></li><li><span>Carefully follow the Instructions for Use when<br>preparing and administering CABENUVA. The suspensions should be injected slowly via<br>intramuscular injection and avoid accidental intravenous administration. Observe patients briefly (approximately 10 minutes) after the injection. If a<br>post-injection reaction occurs, monitor and treat as clinically indicated</span></li></ul><p class="isi_title_unmet728_v1">Hepatotoxicity:</p><ul class="isi_list_unmet728_v1"><li><span>Hepatotoxicity has been reported in patients receiving cabotegravir or rilpivirine with or without known pre-<br>existing hepatic disease or identifiable risk factors</span></li><li><span>Patients with underlying liver disease or marked elevations in transaminases prior to treatment may be<br>at increased risk for worsening or development of transaminase elevations</span></li><li><span>Monitoring of liver chemistries is recommended and treatment with CABENUVA should be discontinued if hepatotoxicity is suspected</span></li></ul><p class="isi_title_unmet728_v1">Depressive Disorders:</p><ul class="isi_list_unmet728_v1"><li><span>Depressive disorders (including depressed mood, depression, major depression, mood altered, mood swings, dysphoria, negative thoughts, suicidal<br>ideation, suicide attempt) have been reported with CABENUVA or the individual products</span></li><li><span>Promptly evaluate patients with depressive symptoms</span></li></ul><p class="isi_title_unmet728_v1">Risk of Adverse Reactions or Loss of Virologic<br>Response Due to Drug Interactions:</p><ul class="isi_list_unmet728_v1"><li><span>The concomitant use of CABENUVA and other drugs may result in known or potentially significant drug interactions (see Contraindications and Drug Interactions)</span></li><li><span>Rilpivirine doses 3 and 12 times higher than the recommended oral dosage can prolong the QTc<br>interval</span></li><li><span>CABENUVA should be used with caution in<br>combination with drugs with a known risk of Torsade<br>de Pointes</span></li></ul><p class="isi_title_unmet728_v1">Long-Acting Properties and Potential Associated<br>Risks with CABENUVA:</p><ul class="isi_list_unmet728_v1"><li><span>Residual concentrations of cabotegravir and rilpivirine may remain in the systemic circulation of patients for prolonged periods (up to 12 months or longer). Select appropriate patients who agree to the required<br>monthly or every-2-month injection dosing schedule because non-adherence could lead to loss of virologic response and development of resistance</span></li><li><span>To minimize the potential risk of developing viral resistance, it is essential to initiate an alternative, fully suppressive antiretroviral regimen no later than 1<br>month after the final injection doses of CABENUVA when dosed monthly and no later than 2 months after the final injections of CABENUVA when dosed every<br>2 months. If virologic failure is suspected, switch the patient to an alternative regimen as soon as possible</span></li></ul><p class="isi_title_part_unmet728_v1">ADVERSE REACTIONS</p><ul class="isi_list_unmet728_v1"><li><span>The most common adverse reactions in adults (incidence &#8805;2%, all grades) treated with CABENUVA were injection site reactions, pyrexia, fatigue,<br>headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash</span></li><li><span>The safety of CABENUVA in adolescents is expected to be similar to adults</span></li></ul><p class="isi_title_part_unmet728_v1">DRUG INTERACTIONS</p><ul class="isi_list_unmet728_v1"><li><span>Refer to the applicable full Prescribing Information for important drug interactions with CABENUVA,<br>VOCABRIA (cabotegravir), or EDURANT (rilpivirine)</span></li><li><span>Because CABENUVA is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not<br>recommended</span></li><li><span>Drugs that are strong inducers of UGT1A1 or UGT1A9 are expected to decrease the plasma concentrations of cabotegravir. Drugs that induce or inhibit CYP3A may affect the plasma concentrations of rilpivirine</span></li><li><span>CABENUVA should be used with caution in<br>combination with drugs with a known risk of Torsade<br>de Pointes</span></li></ul><p class="isi_title_part_unmet728_v1">USE IN SPECIFIC POPULATIONS</p><ul class="isi_list_unmet728_v1"><li><span><b>Pregnancy:</b> There are insufficient human data on the use of CABENUVA during pregnancy to adequately assess a drug-associated risk for birth defects and miscarriage. Discuss the benefit-risk of using<br>CABENUVA during pregnancy and conception and consider that cabotegravir and rilpivirine are detected<br>in systemic circulation for up to 12 months or longer after discontinuing injections of CABENUVA. An Antiretroviral Pregnancy Registry has been<br>established</span></li><li><span><b>Lactation:</b> Potential risks of breastfeeding include<br>HIV-1 transmission, developing viral resistance in<br>HIV-positive infants, and adverse reactions in a<br>breastfed infant</span></li></ul><p class="isi_close_unmet728_v1">Please see <a href="https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF" target="_blank">full Prescribing Information</a> for CABENUVA.</p><p></p><p class="isi_close_unmet728_v1"><b>Reference: 1.</b> Ramgopal MN, Castagna A, Cazanave C, et al. SOLAR 12-month results?randomized switch trial of CAB + RPV LA vs. oral B/FTC/TAF. Presented at: CROI<br>2023; Virtual and Seattle, WA; Oral Presentation.</p><p></p><p class="isi_close_unmet728_v1">Trademarks are property of their respective owners.</p><p class="isi_close_unmet728_v1">©2024 ViiV Healthcare or licensor.</p><p class="isi_close_unmet728_v1">CBRBNNR240003 February 2024</p><p class="isi_close_unmet728_v1">Produced in USA.</p></div></div><div id="adxcel_id_68199663_wrapper_footnote_unmet728_v1" data-wrapper="unmet" style="display:none" class="wrapper_footnote_unmet728_v1 class_hide"><span id="adxcel_id_68199663_footnote_linkparent_unmet728_v1" class="footnote_linkparent_unmet728_v1"><a id="adxcel_id_68199663_footnote_link_unmet728_v1" class="footnote_link_unmet728_v1" href="https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF" target="_blank">Click here</a> for full Prescribing Information.</span><span id="adxcel_id_68199663_footnote_bottomtext_unmet728_v1" class="footnote_bottomtext_unmet728_v1">For US Healthcare Professionals Only.</span></div><div id="adxcel_id_68199663_wrapper_learnwhatsomepatientssaid_unmet728_v1" data-wrapper="unmet" data-cta="C0" style="display:none" class="wrapper_learnwhatsomepatientssaid_unmet728_v1 class_hide"><a id="adxcel_id_68199663_link_learnwhatsomepatientssaid_unmet728_v1" class="link_learnwhatsomepatientssaid_unmet728_v1" href="https://www.cabenuvahcp.com/patient-challenges/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seewhatastudyfound_unmet728_v1" data-wrapper="unmet" data-cta="C1" style="display:none" class="wrapper_seewhatastudyfound_unmet728_v1 class_hide"><a id="adxcel_id_68199663_link_seewhatastudyfound_unmet728_v1" class="link_seewhatastudyfound_unmet728_v1" href="https://www.cabenuvahcp.com/patient-challenges/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_findoutmore_unmet728_v1" data-wrapper="unmet" data-cta="C2" style="display:none" class="wrapper_findoutmore_unmet728_v1 class_hide"><a id="adxcel_id_68199663_link_findoutmore_unmet728_v1" class="link_findoutmore_unmet728_v1" href="https://www.cabenuvahcp.com/patient-challenges/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seewhatastudyfound_unbranded728_v1" data-wrapper="unbranded" data-image="A0" style="display:none" class="wrapper_seewhatastudyfound_unbranded728_v1 class_hide"><a id="adxcel_id_68199663_link_seewhatastudyfound_unbranded728_v1" class="link_seewhatastudyfound_unbranded728_v1" href="https://www.cabenuvahcp.com/patient-challenges/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seewhatastudyshowed_unbranded728_v1" data-wrapper="unbranded" data-image="A1" style="display:none" class="wrapper_seewhatastudyshowed_unbranded728_v1 class_hide"><a id="adxcel_id_68199663_link_seewhatastudyshowed_unbranded728_v1" class="link_seewhatastudyshowed_unbranded728_v1" href="https://www.cabenuvahcp.com/efficacy/head-to-head-switch-study/" target="_blank"></a></div><div id="adxcel_id_68199663_wrapper_seestudyresults_unbranded728_v1" data-wrapper="unbranded" data-image="A2" style="display:none" class="wrapper_seestudyresults_unbranded728_v1 class_hide class_show"><a id="adxcel_id_68199663_link_seestudyresults_unbranded728_v1" class="link_seestudyresults_unbranded728_v1" href="https://www.cabenuvahcp.com/patient-preference/head-to-head-switch-study/" target="_blank"></a></div></div>
</div>
<iframe id="iframe_162315692524" name="iframe_162315692524" data-dv-frm="162315692524" width="0" height="0" src="./saved_resource(6).html" style="display: none;"></iframe><script src="./dvtp_src.js.download" type="text/javascript"></script>
<span id="te-clearads-js-o5l28VJYj9wr" style="padding: 0px; display: none !important;"><script type="text/javascript" src="./ca"></script></span><div style="display:none;width:0;height:0"><img src="./it(1)" border="0" height="1" width="1"></div><script>\nvar img = new Image(0,0);\nimg.src = 'https://pixel.tapad.com/idsync/ex/receive?partner_id=3562&partner_device_id=mBVhoWiZ2h0w&partner_url=https%3A%2F%2Fbh.contextweb.com%2Fsr%3Ftapad%3D1%26pp_tpid%3Dtapad%3A%24%7BTA_DEVICE_ID%7D';\n</script><script async="" src="./ibs_dpid=96678&amp;dpuuid=mBVhoWiZ2h0w"></script><div style="display:none;width:0;height:0"><img src="./insync"></div><div style="display:none"><iframe src="./visitormatch.html"></iframe></div><div style="display:none;width:0;height:0"><img src="./g.pixel"></div><img src="./400066.gif" height="1" width="1" border="0"><div style="display:none;width:0;height:0"><img src="./55660"></div><img id="idx-tag" src="./saved_resource" alt="" \nstyle="display:none !important;"><script type="text/javascript">\n  (function() {\n    var img = new Image();\n    img.src = 'https://trkn.us/pixel/imp/c=21371;p=23248202;cv1=mBVhoWiZ2h0w;idfa=;cid=;ord=%n;nocr=1;r=0cv1G';\n  })();\n</script><script src="./init-31377as4lqmsvjeho7fp.js.download" data-cfasync="false" async=""></script><script type="text/javascript" src="./cs"></script><iframe id="iframe_266340209980" name="iframe_266340209980" data-dv-frm="266340209980" width="0" height="0" src="./saved_resource(7).html" style="display: none;"></iframe><script src="./dvtp_src(1).js.download" type="text/javascript"></script><script>!function(){window.addEventListener("load",(function(){d(),document.body.addEventListener("click",r),top.addEventListener("blur",(function(o){e=!0,n=!1,function(e){t&&r(e)}(o)}),!1),top.addEventListener("focus",(function(){n=!0})),c=setInterval(d,500)}),!1);let t=!1,e=!1,n=!1,o=!1,c=null;const i=["https://a584.casalemedia.com/events/v1/1/578025/189/d0rup68iqcgljg3nhql0/08c23735-2e63-43fd-9b9f-f301661e22c2?"];function u(){document.activeElement.blur(),top.focus(),t=!1}function l(e){t=!0}function r(t){let e=document.body.getBoundingClientRect();if(!document.querySelector(".GoogleActiveViewElement")||(e=document.querySelector(".GoogleActiveViewElement").getBoundingClientRect(),"function"!=typeof t.target.closest||null==t.target.closest("#mute_panel"))){if("number"==typeof t.clientX&&e.width>0&&e.height>0){const n=t.clientX-e.left,o=t.clientY-e.top;if((n<=30||n>=e.width-30)&&(o<=30||o>=e.height-30))return}if(!o){o=!0,clearInterval(c);for(const t of i){const e=document.createElement("img");e.setAttribute("src",t),e.setAttribute("height","1"),e.setAttribute("width","1"),document.body.appendChild(e)}}}}function d(){return Array.from(document.getElementsByTagName("iframe")).forEach((function(t){t.onmouseover=l,t.onmouseout=u}))}}();</script><iframe width="0" height="0" frameborder="0" scrolling="no" src="./usermatch.html" style="display: none;" marginheight="0" marginwidth="0"></iframe><div style="position: fixed; height: 1px; width: 1px; pointer-events: none; z-index: -1; opacity: 0; top: 50%; left: 50%;"></div><div style="position: fixed; height: 1px; width: 1px; pointer-events: none; z-index: -1; opacity: 0; top: 0px; left: 0px;"></div><div style="position: fixed; height: 1px; width: 1px; pointer-events: none; z-index: -1; opacity: 0; top: 0px; right: 0px;"></div><div style="position: fixed; height: 1px; width: 1px; pointer-events: none; z-index: -1; opacity: 0; bottom: 0px; left: 0px;"></div><div style="position: fixed; height: 1px; width: 1px; pointer-events: none; z-index: -1; opacity: 0; bottom: 0px; right: 0px;"></div><script src="./aidem.js.download" async=""></script><script src="https://static.btloader.com/safeFrame.html?upapi=true" async=""></script></body><grammarly-desktop-integration data-grammarly-shadow-root="true"><template shadowrootmode="open"><style>
      div.grammarly-desktop-integration {
        position: absolute;
        width: 1px;
        height: 1px;
        padding: 0;
        margin: -1px;
        overflow: hidden;
        clip: rect(0, 0, 0, 0);
        white-space: nowrap;
        border: 0;
        -moz-user-select: none;
        -webkit-user-select: none;
        -ms-user-select:none;
        user-select:none;
      }

      div.grammarly-desktop-integration:before {
        content: attr(data-content);
      }
    </style><div aria-label="grammarly-integration" role="group" tabindex="-1" class="grammarly-desktop-integration" data-content="{&quot;mode&quot;:&quot;full&quot;,&quot;isActive&quot;:true,&quot;isUserDisabled&quot;:false}"></div></template></grammarly-desktop-integration></html>